feed,title,long_url,short_url
Benzinga,FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older,https://benzinga.com/general/biotech/22/01/25079022/fda-approves-abbvies-upadacitinib-for-refractory-atopic-dermatitis-in-patients-12-years-older,https://j.mp/3tybcJL
